Anna P. Durbin, MD

Background

Centers and Institutes

• Global Health, Center for
• Vaccine Initiative

Clinical Trials Summary

• Evaluating the Safety and Protective Efficacy of a Single Dose of a Trivalent Live Attenuated Dengue Vaccine to Protect Against Infection With DENV-2
• Evaluating the Clinical and Immune Response to Two Dengue Virus Vaccines in Healthy Adults
• Evaluation of the Safety and Immunogenicity of rDEN3?30, a Live Attenuated Monovalent Dengue Virus Vaccine

Additional Academic Titles

Joint Appointment in Medicine

Research Interests

dengue, International health, malaria, vaccines

Lab Website

Anna Durbin Lab - Lab Website

• The Anna Durbin Lab evaluates experimental vaccines through human clinical trials. We have conducted both pediatric and adult clinical trials on vaccines for HIV, hepatitis C, HPV, influenza, malaria, dengue virus, rotavirus and other viruses. We also have a longstanding interest in better understanding the immunologic factors of dengue infection and disease. We're working to identify the viral, host and immunologic factors that cause severe dengue illness.

Research Summary

Dr. Durbin’s research involves the evaluation of experimental vaccines in human clinical trials. At the Center for Immunization Research, she and her team have conducted numerous clinical trials of many different pediatric and adult candidate vaccines. These trials have included vaccines against HIV, hepatitis C, human papilloma virus, influenza, rotavirus, respiratory syncytial virus, dengue virus and malaria. She is primarily interested in vaccines against dengue viruses and malaria, and has very active dengue and malaria vaccine programs at the Center for Immunization Research. They have conducted numerous Phase I live attenuated dengue vaccine trials with the ultimate goal of identifying suitable monovalent vaccine viruses for inclusion in a tetravalent dengue vaccine. In addition, they have conducted many Phase I malaria vaccine trials at their clinical site in Washington, DC. One of Dr. Durbin’s interests is studying the immunopathogenesis of dengue infection and disease. Her team hopes to better understand the viral, host and immunologic factors causing severe dengue illness by extensively characterizing the cellular and humoral responses of volunteers to live attenuated dengue virus vaccines. In addition to their clinical studies, Dr. Durbin’s laboratory is also developing an animal model of dengue using rhesus macaques.

Selected Publications

• Blaney JE, Jr., Durbin AP, Murphy BR and Whitehead SS. “Targeted mutagenesis as a rational approach to dengue virus vaccine development.” Curr Top Microbiol Immunol. 2010;338:145-58.

• Durbin AP, Whitehead SS. “Dengue vaccine candidates in development.” Curr Top Microbiol Immunol. 2010;338:129-43.

• Ellis RD, Martin LB, Shaffer D, Long CA, Kazutoyo M, Fay MP, Narum DL, Zhu D, Mullen GE, Mahanty S, Miller LH, Durbin AP. “Phase 1 trial of the Plasmodium falciparum blood stage vaccine MSP142-C1/alhydrogel with and without CPG 7909 in malaria naïve adults.” PLos One. 2010;5(1):e8787.

• Wright PF, Durbin AP, Whitehead SS, Ikizler MR, Henderson S, Blaney JE, Thumar B, Ankrah S, Rock MT, McKinney BA, Murphy BR, and Schmidt AC. “Phase 1 trial of the dengue virus type 4 vaccine candidate rDEN4D30-4995 in healhty adult volunteers.” Am J Trop Med Hyg. 2009; 81(5):834-41.

Courses & Syllabi

• Special Topics in Vaccine Science, Johns Hopkins Bloomberg School of Public Health, 223.867.01, 1/1/15 - 1/1/16
• Biologic Basis of Vaccine Development, Johns Hopkins Bloomberg School of Public Health, 223.689.01, 1/1/15 - 1/1/16

Honors

• NIH Director's Award, 1/1/10
• National Institutes of Health Merit Award, 1/1/05